Clinical trial Recruiting at 1 site Observational Ages 18 and up

Registry for patients with acute coronary syndrome

Official title: Cardiac Biochemical and Omics-based Biomarkers in Patients Presenting Symptoms of Acute Coronary Syndrome in the Emergency Department (ACS Registry)

Run by University Hospital Heidelberg · NCT06128317 · Data updated 2026-11-12

This study is collecting information about patients with acute coronary syndrome at the University Hospital of Heidelberg to better understand their characteristics and treatment.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2500 (estimated)
SponsorUniversity Hospital Heidelberg
Academic / other
Locations1 site (Heidelberg, Baden-Wurttemberg)
StatusRecruiting
StartedAugust 1, 2014
Main results expectedJanuary 1, 2030
Study endsDecember 31, 2030
Registry record updatedNovember 14, 2023
Trial IDNCT06128317 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older presenting with symptoms of acute coronary syndrome or elevated troponin levels.

Probably not a fit

Patients with acute conditions requiring immediate treatment or those unable to provide informed consent due to mental illness or pregnancy may not benefit from this registry.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to assess the real-world prevalence, demographic characteristics, and management of patients presenting with acute coronary syndrome at the University Hospital of Heidelberg. It involves comprehensive data collection, including clinical parameters and blood samples for analysis of both established and novel biomarkers. The registry is managed by the Department of Internal Medicine III and will serve as a foundation for future clinical studies. Follow-up will be conducted through medical report reviews, phone calls, and postal queries to track patient outcomes.

Why it matters

Potential benefit: If successful, this registry could enhance understanding of acute coronary syndrome and improve patient management strategies.

How similar studies have gone: Other observational studies have successfully characterized acute coronary syndrome, suggesting this approach is validated in the field.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

The study will include consecutive patients who present to the cardiology emergency department at Heidelberg University Hospital with symptoms of acute coronary syndrome or a troponin increase (hs-TnT \>14 ng/L). Additional inclusion criteria are a minimum age of 18 years and providing informed consent through written consent to participate in the study. The following medical conditions are intended to be distinguished from one another:

* Acute myocardial infarction
* Unstable angina pectoris
* Myocarditis
* Heart failure
* Cardiomyopathies
* Pulmonary embolism
* Renal insufficiency
* Supraventricular and ventricular tachycardias
* Hypertensive crisis
* Non-cardiac chest pain

Exclusion Criteria:

Exclusion criteria are defined according to GCP (Good Clinical Practice), i.e., mental illnesses/dementia (lack of capacity to provide informed consent), pregnancy/breastfeeding, as well as acute conditions requiring immediate treatment (e.g., cardiogenic shock).

Where it's running

  • University Hospital of Heidelberg
    Heidelberg, Baden-Wurttemberg, Germany
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.